Articles tagged "Immunosuppression"

2016 American Transplant Congress
The Effect of Immunosuppression Regimen on Iga Nephropathy Recurrence Post Kidney Transplantation.
K. Koutroutsos,¹ A. Kousios,¹ L. Leighton,¹ R. Charif,¹ D. Goodall,¹ T. Cook,² J. Galliford,¹ D. Taube,¹ M. Loucaidou.¹
¹Renal and Transplant Centre, Imperial Healthcare NHS Trust, London, United Kingdom; ²Department of Histopathology, Imperial Healthcare NHS Trust, London, United Kingdom.
Background: Steroid sparing immunosuppression is increasingly used in order to avoid the many well-known side effects of steroids. It has been argued that steroid use…
2016 American Transplant Congress
Conversion to Belatacept as Rescue Therapy in Kidney Transplant Recipients with Severe Graft Dysfunction.
F. Oldhafer,¹ M. Hiss,² A. Schwarz,² H. Haller,² G. Einecke.²
¹Clinic for General, Abdominal and Transplant Surgery, Hannover Medical School, Hannover, Germany; ²Clinic for Nephrology, Hannover Medical School, Hannover, Germany.
Belatacept is a fusion protein that prevents T cell co-stimulation via the CD28 receptor. If used as first-line therapy, immunosuppression with Belatacept is associated with…
2016 American Transplant Congress
Marked Alterations in Gene Expression in Peripheral Blood Leukocytes of Kidney Transplant (tx) Recipients Following Mycophenolic Acid (MPA) Treatment.
K. Sanghavi,¹ B. Wu,¹ C. Dorr,² A. Muthuswamy,² W. Guan,¹ D. Schladt,² R. Remmel,¹ D. Ilke,³ A. Matas,¹ A. Israni,² W. Oetting,¹ P. Jacobson.¹
¹University of Minnestoa, Minneapolis; ²MMRC, Hennepin County Medical Center, Minneapolis; ³Rho.
MPA exerts its immunosuppressive activity by inhibiting IMPDH2 enzyme, halting DNA synthesis in T and B lymphocytes. Cell culture models have shown MPA effects on…
2016 American Transplant Congress
Influence of the Tacrolimus Metabolism Rate on BKV Infection After Kidney Transplantation.
G. Thölking,¹ C. Schmidt,¹ K. Schuette-Nuetgen,¹ D. Pabst,¹ R. Koch,² H. Wolters,³ S. Reuter,¹ B. Suwelack.¹
¹Department of Medicine D, Division of General Internal Medicine, Nephrology and Rheumatology, University Hospital of Münster, Münster, Germany; ²Institute of Biometrics and Clinical Research, University of Münster, Münster, Germany; ³Department of General Surgery, University Hospital of Münster, Münster, Germany.
Introduction: BK virus (BKV) infection is a serious complication following renal transplantation (RTx). The minimization of risk factors that predict BKV infection might help to…
2016 American Transplant Congress
Targeting IFN-g-Expressing TIM-4⁺B Effector (Beff) Cells as a Novel Strategy to Prevent Allograft Rejection.
Q. Ding,¹ K. Mohib,¹ S. Xiao,² V. Kuchroo,² D. Rothstein.¹
¹University of Pittsburgh, Pittsburgh; ²Harvard Medical School, Boston.
B cell depletion can augment or inhibit auto- and allo- immune responses in humans and mice without altering Ig levels. This is likely due to…
2016 American Transplant Congress
Induction Therapy with Depleting Antibodies in Low Immunological Risk Renal Transplant Patients Treated with a Steroid Free Regimen – Comparison of Alemtuzumab vs. Antithymocyte Globulin.
N. Bossini,¹ S. Sandrini,¹ R. Tardanico,² F. Valerio,¹ G. Setti,¹ C. Salviani,¹ S. Possenti,¹ P. Foini,¹ E. Marta,¹ G. Cancarini.¹
¹Division and Chair of Nephrology, A.O "Spedali Civili" and University, Brescia, Italy; ²Division and Chair of II Laboratory of Pathology, A.O "Spedali Civili" and University, Brescia, Italy.
Induction therapy with depleting antibodies reduces rejection rate and potentially improves efficacy of steroid free regimens after renal transplantation.This prospective, single-centre, cohort study evaluated cumulative…
2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
S. Chadban,¹ H. Pilmore,² G. Russ,³ J. Kanellis,⁴ S. Campbell,⁵ P. O'Connell,⁶ W. Lim,⁷ M. Lutherborrow,⁸ N. Kurstjens,⁸ R. Walker.⁹
¹Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Auckland Renal Transplant, Auckland City Hospital, Auckland, New Zealand; ³Central Northern Adelaide Ranel and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; ⁴Renal Medicine, Monash Medical Centre, Melbourne, Australia; ⁵University of Queensland, Princess Alexandra Hospital, Queensland, Australia; ⁶Renal Medicine, Westmead Hospital, Sydney, Australia; ⁷WA Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Australia; ⁸Novartis Pharmaceuticals, Sydney, Australia; ⁹Renal Medicine, Alfred Hospital, Melbourne, Australia.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…
2016 American Transplant Congress
Donor HLA Specific IgM Antibody Measured on Day 14 Post-Transplantation Predicts Poor Graft Survival in HLA-Incompatible Renal Transplantation.
A. Babu, A. Androeu, S. Daga, R. Higgins, D. Mitchell, D. Briggs, N. Khovanova, N. Krishnan.
Renal Medicine, University Hospital Coventry and Warwickshire, Coventry, West Midlands, United Kingdom; Life Sciences, University of Warwick, Coventry, West Midlands, United Kingdom; Histocompatibility and Immunogenetics, NHS Blood and Transplant, Birmingham, West Midlands, United Kingdom; School of Engineering, University of Warwick, Coventry, United Kingdom.
Introduction: Role of IgG antibodies against donor human leucocyte antigens (HLA) is established in renal transplant monitoring. Role of IgM donor HLA specific antibodies (DSA)…
2016 American Transplant Congress
The Impact of a Novel Dual Adenosine Triphosphate-Competitive mTOR Inhibitor (TORKinib) on Alloimmunity and Transplant Survival.
D. Fantus,¹ Y. Ono,¹ S. Yokota,¹ C. Komatsu,¹ H. Turnquist,^1,2 A. Thomson.^1,2
¹Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA; ²Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Background: Rapamycin (RAPA), an immunosuppressive agent, inhibits the mechanistic target of Rapamycin (mTOR), the kinase subunit of two mTOR- containing complexes (mTORC1 and mTORC2). While…
2016 American Transplant Congress
TRANSFORM: A Modern Approach to Evaluate Long-Term Outcomes of Everolimus with Reduced-Calcineurin Inhibitors in De Novo Kidney Transplant Recipients[mdash]Baseline Characteristics.
M. Henry.
On behalf of the TRANSFORM Investigators, Division of Transplantation Surgery, Wexner Medical Center, The Ohio State University, Columbus, OH.
Purpose: Acute rejection and poor graft function are two major risk factors for allograft failure in kidney transplant (KTx) recipients (KTxR). Although, graft survival and…